聚焦超声单侧丘脑底核毁损术治疗不对称帕金森病的初步研究
6个月随访时未发生严重或重度不良事件,治疗侧半身MDS-UPDRS III评分在停药状态改善53%、用药状态改善47%。结论认为该疗法耐受性良好并可能改善运动症状,需大型随机对照试验验证。
要点
- 聚焦超声单侧丘脑底核毁损术在不对称帕金森病中耐受性良好,无严重或重度不良事件。
- 6个月时治疗侧半身MDS-UPDRS III评分停药状态改善53%、用药状态改善47%。
- 常见不良事件包括短暂步态共济失调、头架钉点疼痛和术中短暂高血压。
核心结论
- MRI引导下聚焦超声单侧丘脑底核毁损术耐受性良好,似可改善明显不对称帕金森病患者的运动症状。
- 需大型随机对照试验证实这些初步发现并评估该方法的治疗潜力。
研究设计与样本
- 前瞻性、开放标签初步研究,在西班牙马德里HM Puerta del Sur大学医院CINAC中心进行。
- 主要结局为6个月时的安全性和治疗侧半身运动状态(MDS-UPDRS III,停药和用药状态)。
主要发现
- 6个月随访期间记录38例次不良事件,无严重或重度事件,6个月时仍有7例不良事件。
- 6个月时存在的7例不良事件中,3例与丘脑底核毁损术直接相关:治疗臂停药状态异动症(1例,近6个月时几乎缓解)、治疗臂用药状态异动症(1例,减少左旋多巴剂量后缓解)、主观言语障碍(1例)。
- 6个月时存在的7例不良事件中,4例与医疗管理相关:焦虑和疲劳各1例,体重增加2例。
- 最常见不良事件为短暂步态共济失调(与手术相关,6例)、短暂头架钉点疼痛(与头架相关,6例)、术中短暂高血压(5例)。
临床怎么用
- 对于药物控制不佳、症状明显不对称的帕金森病患者,聚焦超声单侧丘脑底核毁损术可能作为一种无颅骨切口的治疗选择。
- 术后需监测短暂步态共济失调、头架相关疼痛、术中高血压及言语障碍等不良事件。
局限性
- 随访时间仅6个月,长期疗效和安全性未知。
- 研究结果需大型随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ablative neurosurgery has been used to treat Parkinson's disease for many decades. MRI-guided focused ultrasound allows focal lesions to be made in deep brain structures without skull incision. We investigated the safety and preliminary efficacy of unilateral subthalamotomy by focused ultrasound in Parkinson's disease. METHODS: This prospective, open-label pilot study was done at CINAC (Centro Integral de Neurociencias), University Hospital HM Puerta del Sur in Madrid, Spain. Eligible participants had Parkinson's disease with markedly asymmetric parkinsonism. Patients with severe dyskinesia, history of stereotactic surgery or brain haemorrhage, a diagnosis of an unstable cardiac or psychiatric disease, or a skull density ratio of 0·3 or less were excluded. Enrolled patients underwent focused ultrasound unilateral subthalamotomy. The subthalamic nucleus was targeted by means of brain images acquired with a 3-Tesla MRI apparatus. Several sonications above the definitive ablation temperature of 55°C were delivered and adjusted according to clinical response. The primary outcomes were safety and a change in the motor status of the treated hemibody as assessed with part III of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) in both off-medication and on-medication states at 6 months. Adverse events were monitored up to 48 h after treatment and at scheduled clinic visits at 1, 3, and 6 months after treatment. The study is registered with ClinicalTrials.gov, number NCT02912871. FINDINGS: Between April 26 and June 14, 2016, ten patients with markedly asymmetric parkinsonism that was poorly controlled pharmacologically were enrolled for focused ultrasound unilateral subthalamotomy. By 6 months follow-up, 38 incidents of adverse events had been recorded, none of which were serious or severe. Seven adverse events were present at 6 months. Three of these adverse events were directly related to subthalamotomy: off-medication dyskinesia in the treated arm (one patient, almost resolved by 6 months); on-medication dyskinesia in the treated arm (one patient, resolved after levodopa dose reduction); and subjective speech disturbance (one patient). Four of the adverse events present at 6 months were related to medical management (anxiety and fatigue [one patient each] and weight gain [two patients]). The most frequent adverse events were transient gait ataxia (related to subthalamotomy, six patients), transient pin-site head pain (related to the head frame, six patients), and transient high blood pressure (during the procedure, five patients). Transient facial asymmetry (one patient) and moderate impulsivity (two patients) were also recorded. The mean MDS-UPDRS III score in the treated hemibody improved by 53% from baseline to 6 months in the off-medication state (16·6 [SD 2·9] vs 7·5 [3·9]) and by 47% in the on-medication state (11·9 [3·1] vs 5·8 [3·5]). INTERPRETATION: MRI-guided focused ultrasound unilateral subthalamotomy was well tolerated and seemed to improve motor features of Parkinson's disease in patients with noticeably asymmetric parkinsonism. Large randomised controlled trials are necessary to corroborate these preliminary findings and to assess the potential of such an approach to treat Parkinson's disease. FUNDING: Fundación de investigación HM Hospitales and Insightec.
引用
- Martínez-Fernández R, Rodríguez-Rojas R, Del Álamo M, et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurol. 2017. PMID: 29203153. doi:10.1016/S1474-4422(17)30403-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。